Guy Goodwin joins COMPASS Pathways as Chief Medical Officer Post published:July 29, 2021 Post category:Press Release
Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology Post published:July 29, 2021 Post category:Press Release
Levitee Labs Announces Completion of Acquisition of BlockMD Telemedicine Platform Post published:July 28, 2021 Post category:Press Release
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares Post published:July 28, 2021 Post category:Press Release
atai Life Sciences launches InnarisBio to advance delivery of therapeutics for mental health disorders with a licence to develop novel sol-gel intranasal drug delivery platform technology from UniQuest Post published:July 28, 2021 Post category:Press Release
Tryp Therapeutics Announces Q3 2021 Financial Results Post published:July 28, 2021 Post category:Press Release
MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT Post published:July 28, 2021 Post category:Press Release
Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5 Post published:July 28, 2021 Post category:Press Release
Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29, 2021 Under the Symbol FTRP Post published:July 27, 2021 Post category:Press Release
Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent Post published:July 27, 2021 Post category:Press Release